Has Ming Zhang, MD received payments from drug or device companies?

Yes. Drug and device makers reported $42,639 in general payments to Ming Zhang, MD across 345 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Ming Zhang, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Ming Zhang, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Ming Zhang, MD

Interventional Cardiology · Seattle, WANPI 1164614731

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (38.6%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 22 manufacturers reported payments, led by Edwards Lifesciences at 44.7% of the total. Reporting peaked in 2024 at $16,414 and has fallen 62.4% since, to $6,179 in 2025.

$42,639in general payments, 2019–2025

Across 345 payments — averaging $123.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Edwards Lifesciences$19K
Abbott$8K
Boston Scientific$4K
Siemens Medical Solutions USA, Inc.$4K
Abiomed$3K
Angiodynamics, Inc.$2K
plus $3K from 16 others

$650,012in research payments, 2019–2025

Across 139 payments — averaging $4676.35 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Edwards Lifesciences$478K
Boston Scientific$86K
Abbott$80K
Livanova USA, Inc.$5K

What the payments were for

Consulting fees$6,40015%
Speaking & faculty fees$3,8209%
Travel & lodging$15,97637%
Food & beverage$16,44439%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Edwards Lifesciences	107	$19,066
Abbott	83	$7,640
Boston Scientific	59	$4,033
Siemens Medical Solutions USA, Inc.	4	$4,009
Abiomed	37	$2,580
Angiodynamics, Inc.	9	$2,409
Medtronic(2 entities)	13	$1,124
Shockwave Medical, Inc	6	$352
Actelion Pharmaceuticals US, Inc.	2	$267
GE HealthCare	2	$169
Pfizer	2	$158
Merck	2	$150
Nevro Corp.	1	$103
E.r. Squibb & Sons, L.L.C.	1	$86
Amgen	1	$78
Irhythm Technologies, Inc.	3	$77
Novartis	2	$75
United Therapeutics Corporation	2	$69
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)	6	$63
Inari Medical, Inc.	1	$62
Teleflex LLC	1	$38
Janssen Scientific Affairs, LLC	1	$33

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Edwards SAPIEN 3 Transcatheter Heart Valve$12,415
AngioVac$2,222
SAPIEN 3 Ultra RESILIA$2,025
Mitra Clip system$1,726
ACUSON Sequoia Diagnostic Ultrasound System$1,700
GENERAL - THERAPIES$1,687
Impella$1,430
AMPLATZER AMULET$1,142
SC2000$1,140
ACUSON Origin Diagnostic Ultrasound System$1,020
MitraClip$748
Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$709
AMPLATZER Occluders$413
Avalus$304
OPSUMIT$267
UPTRAVI$267
Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$204
THORATEC HEARTMATE 3 LVAS IMPLANT KIT$188
AMPLATZER$184
CARDIOMEMS$178

How this compares

$42,639 in reported general payments places this provider in the 85th percentile of 125 interventional cardiology providers in Washington.

See all interventional cardiology providers in Washington →

Medicare billing

Part B allowed, 2024

$294,225

Medicare patients

873

Services billed

1,535

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Amlodipine Besylate	11	$232

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Seattle

William LombardiSeattle$902K
Kathleen KearneySeattle$448K
Danny DvirSeattle$374K
James McCabeSeattle$289K
Christopher BrownSeattle$266K
Lorenzo AzzaliniSeattle$233K
Sidakpal PanaichSeattle$214K
Christine ChungSeattle$210K
Sameer GafoorSeattle$80K
Ravi HiraSeattle$64K

See the full list for Washington →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →